<DOC>
	<DOCNO>NCT01827202</DOCNO>
	<brief_summary>Forced blockade renin-angiotensin-system ( RAS ) use direct renin inhibition ( DRI ) long propagated effectuate beneficial outcome . However , recent large clinical trial outline harmful effect DRI combination form RAS blockade . To date , information regard DRI RAS-blocking monotherapy limit . Furthermore , remain elucidated DRI angiotensin receptor blocker affect so-called 'classical ' 'alternative ' RAS molecularly . As component 'alternative ' RAS ( e.g . Ang 1-7 ) move research focus , would importance determine angiotensin regulation medical RAS blockade . In prospective , single-center randomize trial 10 week , 24 patient chronic kidney disease ( CKD ) stage III-IV ( eGFR 15-59 ml/min ) randomize take either aliskiren ( 300 mg per day ) candesartan ( 16 mg per day ) two week run-in phase RAS-blockers eliminate . The investigator employ novel mass spectrometry-based quantification method ( run-in 10 week ) capture concentration ten different angiotensin peptide ( include angiotensin I II , angiotensin 1-7 angiotensin 1-5 ) . The investigator hypothesize significant difference exist angiotensin level CKD patient DRI compare angiotensin receptor blocker . Specifically , investigator expect determine regulation alternative RAS represent angiotensin 1-7 proximal versus distal blockade system . Our data might contribute profound understanding result registry clinical trial beyond clinical effect RAS blockade . Further , study 's result might help individualize optimize RAS-blocking therapy strategy CKD patient .</brief_summary>
	<brief_title>RAS Quantification Patients With Aliskiren Candesartan</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Chronic kidney disease stage IIIIV ( define modification diet renal disease ( MDRD ) formula ) Urinary albumin creatinine ratio ( UACR ) &gt; 300mg/g , UACR &gt; 200mg/g already receive RAS blockade Arterial hypertension Age &lt; 18 year Diabetes mellitus type 2 ( define WHO criteria ) Chronic kidney disease stage V ( endstage renal disease ) UACR &gt; 3500mg/g Severe hypertension ( systolic blood pressure &gt; 180mmHg ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>renin-angiotensin-system</keyword>
	<keyword>RAS blockade</keyword>
</DOC>